Bojian Alzheimer's medicine will apply for the market value of 15 billion yuan

Recently, a well-known pharmaceutical enterprise "for the employees who choose to be terminated through negotiation, the preferential scheme corresponding to the termination through negotiation" has been circulated in the industry This is a team structure adjustment document The compensation and transfer procedures related to employee dismissal are as follows: With the deep promotion of the volume purchase policy, for the bid winning procurement enterprises, they can exchange the price reduction for a large area of the national sales market At the same time, the profits of the enterprises are further squeezed If the sales team is maintained again, it is a cost burden It is expected that more and more selected enterprises will abolish the sales team in the future Recently, the general office of the CPC Jiangsu Provincial Commission for Discipline Inspection, the general office of the Jiangsu Provincial Commission of supervision, the Jiangsu Medical Security Bureau and the Jiangsu Provincial Health and Health Commission issued the notice on promoting the sunshine procurement of high-value medical consumables in the whole province, saying that from October this year, we will promote the public medical institutions in the whole province to carry out sunshine procurement on the provincial platform, and put an end to the phenomenon of illegal offline procurement Across the dealer direct payment, Jiangsu Province one vote system to come According to insight database statistics, since the implementation of the new registration and classification of chemical drugs, 389 class 1 chemical drugs have been declared successively, including 24 new chemical drugs, more than 90% of which are in clinical or clinical trials During this period, 9 domestic class 1 innovative drugs were approved for marketing Today, a large number of domestic innovative drugs have emerged, more than 90% of which are currently in the research and development stage, and the research and development progress of these new drugs affects the nerves of pharmaceutical enterprises and investors at the same time On October 22, Bojian and Weicai jointly announced that they planned to submit the listing application document of aducanumab to the US FDA in early 2020 After the news was released, Bojian's share price surged nearly 40% in the pre market trading, and its market value surged by 15 billion US dollars to 56 billion US dollars Its value recovered to March this year After numerous setbacks, who would have expected that Bojian would push a beta amyloid monoclonal antibody, aducanumab, which had already been sentenced to death, to the road of supervision? Recently, HISCO announced that the clinical application of hsk21542 injection, a class 1 new drug independently developed by the company, has been officially accepted and is intended to be used for the treatment of acute and chronic pain According to data from minenet, the total sales volume of terminal anesthetics and painkillers of public medical institutions in China in 2018 is about 30.4 billion yuan Recently, in addition to GSK, Merck, Roche and others have also adjusted their global R & D pipelines, focusing on core areas by selling and cutting down research projects But it is worth noting that these pharmaceutical companies are also focusing on the field of biological medicine Selling, splitting, slimming and transformation have become the key words of multinational pharmaceutical giants Pharmaceutical companies invest heavily in the research and development of new drugs, hoping to recover costs through high drug pricing; patients hope to get treatment in time to improve the quality of life; medical insurance hopes to maintain the normal operation of the fund under the condition of taking care of fairness In the face of different demands from all parties, the decision to include medical insurance can be described as a whole Sometimes progress brings a dilemma From the launch of the world's first I-O drug epimumumab in 2011, to the launch of the world's first PD-1 monoclonal antibody opdivo in 2014, to the destruction of various tumor species one by one, BMS has since become a global leader in the field of i-o It is believed that in the near future, more Chinese cancer patients will usher in the "ice breaking era" of immunotherapy.